Table 1.

Characteristics of currently approved BCMA targeted agents

Drug	Mechanism of action	Regimen of administration	Adverse effects	ORR/CR (%)*	PFS (months)*
Belantamab (ADCs)	Monoclonal antibody conjugated with a cytotoxic agent	Intravenous (every 21 days)	Corneal toxicities Thrombocytopenia	31/3	2.8
Teclistamab (BITEs)	Fully humanized IgG4 bispecific antibody redirecting, CD3-positive T-cells to BCMA	Subcutaneous (weekly)	CRS ICANS Hematological toxicities	63/39	11.3
Idecabtagene Vicleucel (CAR-T)	BCMA targeted CAR-T incorporating anti-BCMA antibody costimulation domain, CD3ζ signaling domain	Single intravenous infusion	CRS ICANS Hematological toxicities	73/33	8.8
Ciltacabtagene Autoleucel (CAR-T)	BCMA-targeted CAR-T-cell product with two single anti-BCMA domain antibodies, CD3-ζ signaling domain costimulatory domain	Single intravenous infusion	CRS ICANS Hematological toxicities	97/67	Not reached

^*Data from the registrational study; CR: complete response; ORR: overall response rate; PFS: progression-free survival.